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A B S T R A C T 
Gene therapy is currently used not only to correct the cellular errors associated with 
tumorigenesis, but to also provide enhanced cellular functions against tumor 
development. Over half of all known cancers have either a loss of function or inactive 
tumor suppressor p53 . In response to various stress or oncogenic signals, the tumor 
suppressor protein p53 mediates cellular response via induction or repression of certain 
genes. Tumor suppressor p53 functions mainly as a transcription factor controlling genes 
involved in D N A repair, senescence, cell cycle arrest, and most importantly, apoptosis. 
Accumulat ion of p53 in the nucleus is necessary for its transcriptional activities; 
however, inactivation of the transcriptional activity of p53 has been shown to be 
associated with tumor formation. Correspondingly, loss of structural stability and 
thermodynamically destabilized p53 mutants are also associated with tumorigenesis. We 
have analyzed the literature on the stability and function of p53. Several research groups 
focus on thermodynamically stabilized p53 , whereas others primarily targeted the 
restoration and enhancement of the transcriptional activity of p53 . Here, we use a holistic 
approach by combining both concepts. W e have successfully constructed plasmids 
extracted from literature, including the thermodynamically stabilized p53_N239Y, and 
the transcriptionally active p53_S46F and p53_S121F. We have also produced novel 
combinations, p53_S46F_N239Y and p53_S46F_S121F for comparison and 
transcriptional activity analysis. Furthermore, we have identified two p53 mutants that 
are thermodynamically stable and with enhanced transcriptional activity compared to 
wild type p53 . 
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After sixty years of laboratory research and collaborative biomedical efforts, a 
clear model for the origin and nature of cancer has been well established. Three models 
for the origin of cancer have been demonstrated. The first model portrays cancer 's origin 
as a complex process involving changes in cellular behavior—that is, epigenetics. 
Epigenetics has not only revealed the molecular dynamics and phenotypic characteristics 
of many cancers, but the changes in cellular behavior and differentiation pathways have 
also become comprehensible [1]. Virologists, on the other hand, have delineated an 
alternative model for the origin of cancer. 
Distinct cancer-causing viruses with both D N A and RNA have been demonstrated 
to trigger tumor formation in both humans and different types of animals. Viruses such as 
the Epstein-Barr Virus, SV40, Human T-Cell Leukemia Virus, Shope Papilloma virus, 
Kaposi and Rous Sarcoma Virus have been shown to initiate tumor formation [1 , 2] . The 
last and most noteworthy model of cancer 's origins was the perspective that cancer is a 
result of a genetic disorder. This last model linked the relationship between changes in 
D N A primarily generated by carcinogens and mutagens with an apparent neoplasm [ 1 , 2 ] . 
The discovery of these cancer-causing genes, oncogenes, also found inside viruses, united 
both the concepts of cancer-causing viruses and genotoxically produced oncogenes. 
Cancer genetics, thus, ubiquitously gained considerable attention and analysis. 
The discovery of oncogenes brought about a tremendous shift in cancer research. 
As the race and search for identifying oncogenes intensified in the early 4 7 0 ' s , mutagenic 
carcinogens and their mechanisms of tumor formation remained unclear. Multistep 
tumorigenesis, a process by which cells undergo various stages of alteration to become 
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malignant, was initially proposed by Carl O. Nordling [1]. Multistep tumorigenesis was 
later verified by several researchers including Peter Armitage and Richard Doll [1 , 3-5]. 
Alfred Knudson furthermore demonstrated that retinoblastoma was caused by at least two 
independent mutations as cells transformed from a normal cell to a cancerous cell [6, 7] . 
A single oncogene, unaccompanied with any other genetic mutation, was demonstrated to 
be insufficient to initiate neoplastic behaviors [1 , 3] . 
Interestingly, similarities were found analyzing the succession of mutations 
required for the formation of many cancers. As a cell undergoes various stages over t ime, 
cancer cells were found to accumulate two significant types of mutations. Subsequent to a 
primary mutation that produced an oncogene, the second mutations usually affected 
genes that controlled cellular proliferation. Key mutations were identified in genes that 
negatively controlled cellular proliferation, named tumor suppressor genes (TSGs). 
Mutations in TSGs were found to be responsible for the uncontrollable cellular 
proliferation seen in all cancer cells [1, 3] . 
A single normal function of TSGs was in some cases sufficient enough to restore 
some of the normal function of cellular proliferation; however, a loss of function of both 
normal genes, a recessive trait, severely reduces tumor suppression activity of TSGs [1]. 
The discovery of T S G ' s has been tremendously significant in the progress of cancer 
therapeutics. Eliminating or suppressing cancers thus requires selective and specific 
therapeutics that not only target the basis of the tumor formation, but methods that also 
correct the cellular errors associated with uncontrollable cellular proliferation. Current 
research in our lab, Dr. Carol L im 's Lab, is focused on correcting these cellular errors. 
The Lim Lab has previously shown that in chronic myelogenous leukemia cells (CML), 
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change in location of the normally oncogenic Bcr-Abl protein from the cytoplasm to 
nucleus converts Bcr-Abl into an apoptotic factor [8]. Bcr-Abl is itself an oncogene and 
is a product of the translocation of chromosomes 9 and 22. One goal of our lab is to use a 
ligand inducing "protein switch" that moves Bcr-Abl from the cytoplasm to nucleus, thus 
converting the oncogene to an apoptotic factor via cytoplasmic depletion and nuclear 
trapping of Bcr-Abl proteins [8-10]. 
Furthermore, and more holistically, we are simultaneously targeting the tumor 
suppressor protein p53 to the nucleus and the mitochondria for cancer therapy. The 
human TP53 gene is one of the most frequently altered genes found in all human cancers 
(F igure 1). Loss of transcriptional activity and structural instability (temperature 
sensitive mutants) are associated with tumorigenesis. We have analyzed the literature on 
the stability and function of p53. Several research groups focus on thermodynamically 
stabilized p53, whereas others primarily targeted the restoration and enhancement of the 
transcriptional activity of p53 . Here, we investigate both the thermodynamically 
stabilized as well as the transcriptionally active mutant p53 for the capabilities to 
transcribe the p53-promoter sequence known to correlate with apoptosis. Furthermore, 
we have generated p53 constructs with both of these combinations. Is the most optimal 
p53 tumor suppressor protein for future cancer therapeutics a transcriptionally active p53 , 
a thermodynamically stabilized p53, or a combination of both? 
The Tumor Suppressor Protein p53 
For more than twenty-five years, the tumor suppressor protein p53 has remained 
the most complex and researched protein in all of cancer therapeutics [11]. The function 
and integrity of p53 to prevent cancer structure is dependent on the quantity, structure, 
and activity of the p53 proteins in the cell (F igure 1). In response to various stress or 
oncogenic signals, such as D N A damage or hypoxia, the tumor suppressor protein p53 
mediates cellular response via induction or repression of certain genes [12]. Tumor 
suppressor p53 functions as a transcription factor for many genes controlling D N A repair, 
senescence, cell cycle arrest, metastasis inhibition, and most importantly, apoptosis [12, 
•13]. Accumulation of p53 in the nucleus is necessary for its transcriptional activities; 
however, p53 can also induce apoptosis via transcriptionally-independent pathways [12]. 
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F igu re 1: T u m o r S u p p r e s s o r p53 M u t a t i o n s a n d C a n c e r . Greater 
than fifty-percent of all cancer have a TP53 mutation. TP53 mutations 
are common in many of the cancers seen both in developing and 
developed countries. Database maintained at the Institut Curie, Paris 
France. Reprinted with the permission of Dr. Soussi, website, 
http://p53.curie.fr, July 2010. 
Through the induction of p53 , apoptosis can occur via two major pathways, 
extrinsic and intrinsic. The extrinsic pathway involves three trans-membrane death 
receptors (Fas, DR5, and PERP) and caspase-8 mediated apoptotic cascade [14]. The 
intrinsic pathway, on the other hand, is through the mitochondria and Bcl-2 pro-apoptotic 
family. Centered on the Bcl-2 family, Bax, Noxa, and P U M A are the pro-apoptotic 
mitochondrial members [14]. In addition, p53 itself can induce apoptosis by acting 
directly at the mitochondria [15]. Mitochondrial permeabilization occurs as p53 interacts 
with Bcl-xL and Bcl-2 to change the mitochondrial membrane potential and release 
cytochrome c [15]. 
The TP53 gene is located on human chromosome 17p l3 [13, 16, 17]. Tumor 
suppressor p53 contains 393 amino acid residues, encompassing three distinct regions 
(F igure 2) [18]. The first region is the N-terminus region with several sub-domains. Of 
most significant sub-domains in the N-terminus region are the transactivation domain 
(TAD), and the proline-rich domain (PRD) [12, 13]. 
M B D : M D M 2 Binding Domain NES: Nuclear Export Signal 
( TAD ) 
Amino Terminus C-Terminal 
0 17 63 102 DBD 293 313 323 393 
DBD: D N A Binding Domain 
PRD: Proline-Rich Domain TD: Tetramerization Domain 
NLS: Nuclear Localization Signal 
F igu re 2 : Ful l L e n g t h p 5 3 . The p53 protein holds three distinct regions with several 
sub-domains in each region. The N-terminus region (residues 1-93), D N A Binding 
Domain (residues 94-293), and the C-terminus region (residues 294-393). Reprinted 
with the permission of Mohanad Mossalam, Lim Lab. 
The N-terminus region of p53 is approximately 93 amino acid residues in length 
and the majority of its structure is naturally unfolded [19]. The T A D region (residues 1-
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60) is both a negative regulator and activator of transcription activity of p53 via M D M 2 
and p300/CBP protein interactions, respectively [2, 12]. The N-terminus region that 
encompasses the TAD section interacts with various proteins including MDM2, a 
ubiquitin ligase protein that is responsible for tagging p53 for degradation 
(ubiquitination) [2]. Depending on tissue type, normal half-life of p53 is 6-30 minutes 
and is auto-regulated by the M D M 2 protein [2]. Loss or inhibition of M D M 2 through up-
regulation mechanisms produced by stress signals significantly extends the half-life of 
the p53 protein from minutes to hours [2]. 
Conversely, the proline-rich domain (PRD) (residues 60-93) contributes to the 
apoptotic function of p53 [12, 13]. This region may contribute to apoptosis in a DNA-
damage dependent manner [11-13]. The PRD is a region that has five copies of PXXP 
(P=proline; X=amino acid residue) and interacts with the co-activator protein p300 [13]. 
Activation of p53 via the N-terminus region, especially in the P R D region, induces or 
inhibits the transcription of more than 150 genes [11, 20] . 
Subsequent to the N-terminus region is the evolutionarily conserved region 
designated as the DNA binding domain (DBD). The D B D region is the most significant 
region maintaining p53 structure and function against various different cancers. Although 
p53 is transciptionally active as a tetramer, the DBD region consists of the basic region 
required for D N A binding. The D BD consists of an "immunoglobulin-l ike p-sandwich" 
with several loops stabilized by a zinc ion [12]. The folded D B D region is not only 
responsible for sequence-specific D N A binding, but also protein-protein interactions 
[11]. Furthermore, the DBD region recognizes and binds to a double-stranded D N A 
sequence in the nucleus. The DNA sequence of each strand consists of a single 10 base 
pair region, producing a palindrome. The palindrome segment is generally a -
R R R C W W G Y Y Y - region, where R represents a purine (A, G), Y represents pyrimidines 
(C, T), and W represents either an A or a T [11-13]. In almost all cancers with a mutated 
p53 , the probability that a missense mutation resides within the D B D of p53 is greater 
than 8 0 % (F igu re 3) [21]. The p53 D B D is quite unstable with a denaturing melting 
temperature (Tm) of approximately 42°C [18]. A significant number of p53 D B D 
mutations are responsible for the thermodynamically destabilized protein that unfolds at 
body temperature [18]. 
SOMATIC MUTATIONS - Codon distribution of single base substitutions (n-22356) 
159152331 39 47556371 798795105117128140152163175186198 210221 233244 256 268279291 302 314 326337 349360 372 384 
codon number 
(C) IARC TP53 Database, R15 release, November 2010 
F igu re 3 : Mos t C o m m o n M u t a t i o n s . The six mutations above have been 
designated the 'hotspot ' mutations. These six mutations (residues 175, 248, 273, 
245, 249, and 283) have the highest frequency of occurrence in cancers. Majority of 
mutations are located in the D BD region. Reprinted with the permission of Dr. 
Olivier, website, http://www-p53.iarc.fr/, November 2010. 
Lastly, the C-terminus region of p53 is primarily responsible for p53 
tetramerization [12]. The tumor suppressor protein p53 is only active as a tetramer in the 
nucleus. The C-terminus is also a regulatory region consisting of three nuclear 
localization signals (NLS) for the import of p53 into the nucleus [12, 13]. The 
tetramerization domain itself encompasses a nuclear export signal (NES) that is masked 
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when p53 ' s homotetramerizes [13]. The natively unfolded region of the C-terminus is 
also the location where M D M 2 is thought to tag lysine residues (ubiquitinates) for 
proteasomal degradation of p53 [22]. Furthermore, the C-terminus region is considered 
nonessential for p53 stability but is thought to "fine-tune" p53 transcriptional activity 
[23]. 
Understanding the structural and molecular complexity of p53 has provided 
insight into how we can develop cancer specific therapy. Selective and specific targeting 
has been described as the ultimate aim of cancer research and therapy [24]. 
Understanding and targeting the causal events that transform a normal cell into an 
invasive malignant cell has been shown to be promising, especially with the current 
computational advancements in research. Chronic myelogenous leukemia (CML) and 
breast cancer (BC), via targeting Bcr-Abl selective tyrosine kinase inhibitor and HER2 
down-regulating targeting drugs, respectively, remain successful exemples of selective 
and specific drug targeting [24]. Furthermore, tumor suppressor p53 has been an 
effective gene therapy target method against cancers associated with the lungs, head and 
neck squamous cell carcinoma, and ovaries [25-27]. 
TP53 and Cancer 
According to the International Agency for Research on Cancer (IARC), their 
TP53 mutation database (www-p53.iarc.fr) encompasses more than 27,000 somatic 
mutations and 597 germ-line mutations. Of these mutations, over 2000 functional p53 
mutant proteins were found. Furthermore, the majority of mutations found not only 
produced full length p53 proteins but also had various properties and functions. Over 
7 5 % of the mutations were reported as amino acid substitutions or missense mutations 
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(F igure 4) [21]. Correspondingly, the database at the Institut Curie in Paris, France 
(http://p53.curie.fr/) has reported over 30,000 TP53 mutations with more than 1500 
different types of p53 mutants [28]. Likewise, a majority of the mutations were found to 
be amino acid substitutions. 
Greater than 8 0 % of TP53 mutations reside between residues 100-300 of the 
DNA binding domain (DBD) of p53 [28, 29] . Breast cancer, the third most common 
tumor in the world, is the cancer our lab has selected for p53 mutant therapy. Breast 
cancer (BC) represents the most applicable therapeutic method for all cancers with TP53 
mutation because the pattern of mutational events and restoration of p53 parallels the 
high frequency of missense mutations (F igu re 5). Furthermore, mutations in the TP53 
gene in BC patients have been shown to have the poorest prognosis in comparison to 
many other cancer types [21]. Correspondingly p53 mutation in BC is quite complex, 
especially during metastasis; therefore selective p53-targeted gene therapy is quite 
promising [30]. 
SOMATIC MUTATIONS - MUTATION EFFECT / 26608 mutations 
(C) IARC TP53 Database, R15 release, November 2010 
Figure 4: Mutation Types. A comparison of the most common somatic 
mutations seen in human cancers. Base-pair substitutions represent 
approximately 7 3 % of all mutations in TP53. Reprinted with the permission 
of Dr. Olivier, website, http://www-p53.iarc.fr/, November 2010. 
10 
Breast cancer accounts for 2 3 % of all types of cancers cases globally [31]. 
According to the American Cancer Society, breast cancer in women living in the United 
States accounts for 2 5 % of cancer cases, that is, one in four women with cancer. 
Furthermore, in 2010, approximately 208,000 new cases of invasive cancers were 
diagnosed and nearly 39,000 women died from breast cancer in the United States. 
Although patients with non-invasive cancer have a significantly better treatment and 
survival rate in comparison to patients with invasive cancers, the severity of the disease is 
dependent on the stage of the cancer. The T N M staging system developed by the 
American Joint Committee on Cancer (AJCC) is the most common method currently 
used. The first phase of determination is based on letter coding T (tumor size and distance 
from organ), N (lymph node connection), and M (metastases). After the initial phase, rise 
in stages (0, I, II, III, and IV) correlates with increase severity. The uncontrollable 
proliferation and the ability of breast cancer cells to metastasize has been the greatest 
challenge to breast-conserving surgery, hormonal therapy, and chemotherapy [32]. The 
p53 protein is not only anti-metastasis, but correcting the cellular errors in BC may 
perhaps be the most effect method against all stages of breast cancer. 
The most common 'hotspot ' missense mutations of all cancers are located on 
residues R175, R248, R273, G245, R249, and R283 (F igure 3) [12, 28] . Of the six most 
common TP53 'hot spot ' mutations, breast cancer holds three of the six mutations with a 
high frequency distinctively at residues 175, 248, and 273 (F igure 5). Each cancer type is 
clearly specific and holds a distinctive p53 mutant with corresponding oncogenes; 
however p53 mutants have been classified into two different categories. The first class of 
mutations are those that affect the transcriptional activity of p53 , identified as contact 
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mutations (CM) [12]. The 'hot spot ' mutants R273C, R273H, R248W, and R248Q are 
contact mutations that remove or alter the ability of p53 to interact with essential D N A — 
that is, these mutants are deficient in their transcriptional abilities in the nucleus of the 
cell [12]. The second class of mutations as stated earlier are thermodynamically 
destabilized p53 that carry structural mutations (SM) and affect the overall architecture of 
p53 [12]. Examples of SMs are R282W, G245S, V143A, and R175H mutations present 
in various cancers such as lung, breast, colorectal, and prostate and liver cancer [28]. On 
the basis of these mutational classes and the instability of the p53 protein, restoration and 
reactivation of p53 require transcriptional reactivation as well as thermodynamic 
stabilization. 
The UMD p53 database 
Linn Hjortsberg and Thierry Soussi, 2008 http://p53.fre8.fr 
Figure 5: Breast Cancer. Of the six 'hotspot' mutations listed earlier for all 
cancers (residues R175, R248, R273, G245, R249, and R283), three are most 
common in breast cancer (R175, R248, R273). Reprinted by the permission 
from Dr. Olivier, website, http://www-p53.iarc.fr/, November 2010. 
Restoration: Thermodynamically stabilizing p53 
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The stability of wild type p53 DBD region is 9.8 kcal/mol approximately at 10°C 
(AG D - N H 2 ° free energy of p53 unfolding in the presence of urea) [33, 34] . Several articles 
have highlighted the irreversible denaturing of p53 D BD region with increased 
temperature [35]. The DBD region becomes less stable with increased temperature which 
may lead to loss of function of the protein [35]. The normal human body temperature is 
37°C and increases slightly with exercise, thus, the proposal of a 'superstable ' 
( thermodynamically stabilized) p53 protein by various researchers. Furthermore, several 
oncogenic p53 mutants including R175H, C242S and R248Q are destabilized 
thermodynamically by 3.0, 2.9, and 1.9 kcal/mol, respectively, as compared to wild-type 
p53 AG D _ N H 2 ° unfolding [35]. 
Crystal structures of mutant p53 proteins, p53_N239Y and p53_N268D, have 
been shown to increase the thermodynamic stability of p53 via hydrophobic packing and 
alternative hydrogen bonding, respectively [33]. Mutant p53_N268D increases the 
AG D _ N H 2 ° by 1.21 kcal/mol (10.98 kcal/mol at 10°C ) while p53_N239Y increases it by 
AG D ^ N H 2 ° by 1.37 kcal/mol (11.14 kcal/mol at 10°C) [36]. Furthermore, a double mutant 
construct containing one cancer hot spot mutation G245S and thermodynamically stable 
p53_N239Y showed a restored activity of the p53 protein—p53_N239Y acts as a second-
site suppressors for the cancer hot spot G245S and restores the function of p53 [34]. 
Additionally, p53 paralogs, p63 and p73 , were found to have two mutations that 
can increase the stability of p53 by 17°C [12]. These two mutations are buried groups 
located on Y236F and T253I and increase stability of p63 and p73 by 1.6 kcal/mole 
approximately [12, 37] . Although this double mutation is stated to be additive in its 
contribution to thermodynamic stability, only the thermodynamic stability of the single 
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mutation Y236F mutant is known. This mutant, Y236F, holds a thermodynamic stability 
of 0.27 kcal/mole while the stability of p53_T253I remains unknown or unmeasured for 
its AG D - N H 2 ° [34, 36] . Furthermore, all thermodynamically stable mutations listed in 
literature are naturally occurring amino acid substitutions isolated by comparing the 
stability of various p53s in 23 species [36]. We have therefore engineered the super-
stable p53_N239Y, p53_Y236F, and p53_T253I mutants to analyze their transcriptional 
activity which should correlate with p53 apoptosis. These superstable mutants should 
show enhanced transcriptional activity. 
Reactivation: Enhancing Transcriptional Activity 
Other super p53 mutants have been identified with enhanced transcriptional 
activity. Several articles have highlighted the correlation between transcriptional activity 
and apoptosis [38]. Mutations in the p53 proteins that affect the transcriptional activity 
usually strengthen, complement, or substitute bonds or different linkages in the p53 
protein-DNA contact regions [12]. Key p53 residues (Lys-120, Ser, 241 , Arg-248, Arg, 
273, Ala-276, Cys-277, and Arg-280) either make direct contact with D N A or through a 
water mediated D N A contact [12]. 
Interestingly, a " 1 2 I F mutant" with decreased M D M 2 transcription and enhanced 
apoptotic ability was one of the first of ' super ' p53s identified [38]. The 121F mutants 
demonstrated enhanced apoptotic ability and strong activation for the Rad (a muscle-
specific GTPase) and PIR121 (an open reading frame) genes. Although two new genes 
not previously recognized as p53-targeted genes were identified, selective induction and 
sequence-specificity of p53 transcription was also observed [38]. Furthermore, 12IF 
mutants were defective on the p2 promoter for the transcription of M D M 2 by the auto-
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regulatory mechanism of p53 [38]. Extended p53 half-life due to decreased M D M 2 was 
linked to the increased apoptotic function of 121F mutants. Furthermore, 12IF mutants 
are not cell type-specific and can induce apoptosis in cancer cells that are resistant to 
exogenous introduction of wild-type p53 [38]. Although defective in the p2 promoter for 
M D M 2 , the transcriptional activity on a p53 promoter itself remains unknown. 
A mutation on the N-terminus region p53_S46F has also been identified as a 
'super p 5 3 ' for a number of p53-targeted genes [39]. p53_S46F was also demonstrated to 
have enhanced apoptotic ability in various cells lines including HI299 , L C I 7 6 and A549 
(all lung cancer cell lines), HepG2 (hepatoblastoma), and the colon cancer cell lines, 
LS174T and HCT116 [39]. Furthermore, increased transcriptional activity of proteins 
involved in the mitochondrial apoptotic pathway including Noxa and two other p53 -
mediated transcript proteins, p53AIPl , p53RFP were observed [39]. Furthermore, 
enhanced serine 15 phosphorylation and decrease in p21 /WAFl (regulator of cell-cycle 
and p53 competitor) were detected, indicating that phosphorylation especially at the 
serine-15 site increases p53 activity [39]. Increased transcriptional activity of p53 not 
only correlated with apoptosis, but a wide network of proteins responsible for the 
regulation of cellular proliferation including cell-cycle arrest are also activated and 
regulated by p53 . Higher p53-targeted transcriptional activity was observed in p 5 3 R D L l , 
p 2 1 / W A F l , p53RFP, p53AIP l , Bax, Puma, Noxa, p 5 3 D I N P l , and p53R2 [39]. 
We have generated both the p53_S12F and p53_S46F mutant constructs. 
Furthermore, we have also produced a novel combination of two mutants: 
p53_S46F_S121F and p53_S46F_N239Y. In theory, phosphorylation of serine 15 as well 
as the DNA affinity of 121F in our p53_S121F_S46F should create a highly optimal p53 
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that can not only induce apoptosis in various cell lines, but also hold higher 
transcriptional activity across a broader spectrum of genes that regulate the cell-cycle. 
Clearly the most favorable and perhaps the best p53 for gene therapy is the introduction 
of a thermodynamically stable as well as transcriptionally active protein: 
p53_S46F_N239Y. T a b l e 1 below summarizes a list of our mutations and constructs. 
T a b l e 1. 
Restoration and Reactivation: p53 constructs 
Type Construct Mutation 
p53 N239Y N ^ Y 
Thermodynamically Stabilized p53 Y236F Y ^ F 
p53_T253I T ^ I 
p53 S12F S ^ F 
Transcriptionally Active p53_S46F S->F 
p53 S46F N239Y S ^ F and N ^ Y 
Combinations p53_S46F_S121F S->F and S ^ F 
* Amino acid substitution of corresponding numbers in respective order. 
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MATERIALS A N D M E T H O D S 
LB Broth and Agar Plates 
Bacterial medium was prepared by using 12g of LB Broth (SIGMA Life Sciences) in 600 
ml of double-distilled water (ddH20) followed by autoclaving. After cooling, 3 ml of 
kanamycin was added to complete the broth. Correspondingly, LB agar plates (batches of 
20 plates) contained 24 g of LB agar in 600 ml of d d H 2 0 and autoclaved for 20 min at 
121°C. 3ml of kanamycin was added. 
Plasmid Constructs 
Specific mutations in full length p53 plasmid (a gift from Dr. S. J. Baker, Addgene) 
containing ColEl origin, M C S , F l ori, SV40 early promoter, and KanR) were made 
using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, Agilent Tech.). 
Mutagenic primers were designed on ApE Plasmid editor for length, Tm, and % G C (see 
primer list below). PCR matching (PTC-200 Peltier Thermal) and BIO-RAD (CI000) 
thermal cycler instruments were used for DNA amplification. PCR reaction conditions 
are listed below in T a b l e 2. After temperature cycling, the reaction was placed on ice for 
2 minutes to cool the reaction to an approximate temperature of 37°C. 
T a b l e 2. 
PCR Reaction Conditions: QuikChange Site-Directed Mutagenesis 
Segment Cycles Temperature Time 
1 1 95°C 30 sec 
2 12 95°C 30 sec 
55°C 1 min 
68°C n5 min 
n
 Minutes/kb of plasmid length, p53 plasmid was used for all missense mutation. The length of p53 plasmid 
is 5151 bp in length. 
17 




































*Plasmid P53N239Y was used to introduce the second mutation 
**Plasmid p53_S46F was used to introduce the second mutation. 
Oligonucleotide primers, complementary to strands of the vector, were extended via 
PfuTurbo DNA polymerase. Mutated plasmids are thus obtained by incorporating the 
oligonucleotide primers in the extended DNA. Parental D N A is digested by the Dpn I 
endonuclease, 5 - G m 6 A T C - 3 ' , specific for methylated and hemimethylated DNA. The 
circular, nicked double-stranded D N A was then transformed into XL 1-Blue 
supercompetent cells, and subsequently plated. Prepared controlled reaction mix can be 
found in Tab le 3 below. 
T a b l e 3 . 
Control Reaction: QuikChange Site-Directed Mutagenesis 
Construct Forward Primer Backward Primer PfuTurbo DNA polymerase dNTP Dpn I 
p53 N239Y 125 ng 125 ng 2.5 U/ul 1 ul 10 U/ul 
p53 Y236F 125 ng 125 ng 2.5 U/ul lul 10 U/ul 
p53 T253I 125 ng 125 ng 2.5 U/ul lul 10 U/ul 
p53 S12F 125 ng 125 ng 2.5 U/ul lul 10 U/ul 
p53 S46F 125 ng 125 ng 2.5 U/ul 1 ul 10 U/ul 
D N A Purification 
The next day, single colonies in 5 ml of LB-kanamycin broth were incubated at 37°C for 
24 hours, spun for 15 min at 35000 rpm at 4°C. Zippy Plasmid miniprep kit was used to 
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isolate plasmid as follows. After centrifugation of the 5ml bacterial culture grown in LB-
kanamycin broth, 600 ul of ddFI^O was resuspended in the in bacterial pellet. 100 ul of 
7X lysis buffer was added after transfer in a 1.5 ml microcentrifuge tube. 350 ul of cold 
neutralization buffer followed by 16,000 g for 4 minutes pelleted the debris. 200 ul of 
Endo-Wash Buffer, 400 ul of Zyppy™ wash buffer were used further to wash and collect 
the purified DNA. 30 ul of ddF^O and 30 seconds centrifuge eluted the plasmid DNA. 
Plasmid concentrations were measured using the Thermo-Scientific NanoDrop 2000 
spectrophotometer. Using l.Oug of plasmid and 10 pmol of primer; mutations in the 
plasmids were verified by sequencing from The University of Utah HSC Core Research 
Facilities. Subsequently, isolation of DNA in greater amounts was carried out using 
HiPure MaxiPrep Kit (Invitrogen). Colonies obtained from master plates were grown in 
150 ml of LB-kanamycin broth for 24hr at 37°C and centrifuged, the bacterial lysate were 
cleared via the binding the D N A directly to the chromatographic anionic resin. Following 
centrifugation at 4,000 x g for 10 minutes purification preceded similar to the miniprep 
protocol and using the Precipitating DNA Using Precipitator Module, and with 500ul of 
ddF^O as the final step. 
Cell Culture 
Invasive breast ductal carcinoma, MCF-7 cells (http://www.atcc.org/), were prepared and 
cultured in RPMI 1640 for transcriptional analysis. Adherent MCF-7 with mislocalized 
p53 was maintained at 37°C in air, 9 5 % and carbon dioxide, 5 % (http://www.atcc.org/). 
Doubling time of MCF-7 is approximately 29 hours. RPMI 1640 containing 10% FBS, 
1% L-glutamine, 1% penicillin, 0 . 1 % streptomycin, and 4mg/L of insulin was used to 
grow MCF-7cells. MCF-7 cells were split 1:3 every 48 hours. Cells were first washed 
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with 10 ml PBS and treated with 3 ml of trypsin for a 5 minutes (to detach cells), 
followed by the addition of 7 ml RPMI medium and subsequent splitting. 
Plating 
After trypsinization, MCF-7 cells were placed in 50ml tubes then centrifuged for 7 min at 
3000g at 4 °C. Cells were counted using a hemacytometer. Approximately l x l O 5 cells 
were plated into three wells for each construct in a 96 well-plate (white) for 24 hour 
before lipofectamine transfection. 
Lipofectamine and Luciferase activities 
24 hours after plating, media was removed, and 80ul of RPMI with FBS only was added 
to each well. Optimem (80 ul), D N A plasmid (175ng), reporter master mix (8 ul), Plus 
reagent (1 ul), and LTX (2.5 ul) were all mixed in a microfuge tube multiplied by four 
(three wells were used, however, all solutions were divided by four to prevent shortage) 
and placed in each of the wells. Reporter mix was prepared by adding 10 ul of p53 -
reporter plasmid in 90 ul of ddF^O with 1 ul of renilla in 99 ul of ddF^O. To examine the 
transcriptional activity of p53 , PathDetect® p53 Cis-Reporter plasmid (Stratagene) was 
co-transfected with plasmid with respective mutations. The PathDetect® reporter 
contains a synthetic promoter with repeats of the transcription recognition sequences for 
p53 fused to the luciferase gene. Firefly luciferase was normalized to renilla luciferase. 
Dual-Glo Luciferase Assay System® (Promega) was used for cell lysates and quantitative 
analysis used Lumino-program system. Luciferase assays was performed 2 t imes in 
triplicate for each plasmid transfected per cell line. 
RESULTS 
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I have successfully constructed all seven plasmids extracted from literature and 
novel constructs listed above containing their following respective mutations (F igure 6). 
We expected our novel p53_S46F_S121F to have the highest transcriptional activity. The 
double mutant, p53_S46F_S121F, should not only exhibit elevated transcriptional 
activity due to the enhanced serine 15 phosphorylation by the addition of the S46F 
mutation but the S121F mutant should also contribute to transcriptional activity via its 
D N A affinity by for p53 binding sites [38, 39]. An increased level in serine 15 
phosphorylation has been suggested to stabilize and enhance the transactivation of the 
p53 protein [39]. Conversely, we expected the thermodynamically stabilized p53_N239Y 
constructs to have a similar or slightly greater transcriptional activity than the wild-type 
perhaps due to additional "hydrophobic packing interactions at the DNA-binding 
surfaces" [12, 35, 36] . However, we expected our double mutant constructs 
p53_N239Y_S46F to demonstrate enhanced transcriptional activity because of the 
reactivation abilities of S46F mutants discussed previously and the stabilized D BD core 
domain contributed by N239Y. 
Fire-fly reporter vector containing the p53 promoter-gene was used for 
transcriptional analysis. PathDetect® reporter containing a synthetic sequence of the p53 
promoter was fused to the luciferase gene. PathDetect® p53 Cis-Reporter plasmid 
(Stratagene) was co-transfected with plasmid constructs. The p53-reporter gene is mainly 
used to determine a constructs interaction and regulatory potential of the DNA-sequence. 
This reporter gene also identifies constructs that are sequence specific for the p53 
promoter. 
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SV40 early promoter 2816..3012 
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F1 ori 2505...2199 
p53_S46F N239Y 
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p53 5151 bp 
Kan/neoR 3050...3841 
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p53 613. .1794 
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F1 ori 2505..2199 
p53 
Figure 6: Plasmid Constructs. Full length p53 plasmid containing ColEl origin, MCS, Fl ori, 
SV40 early promoter, and KanR was used to introduce the mutations. ApE Plasmid Editor 
generated images, http://biologylabs.utah.edu/iorgensen/wayned/ape/. 
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Thermodynamically stabilized p53_T253I has shown the highest transcriptional 
activity (F igure 7). The relative transcriptional activity of p53_T253I is higher than the 
wild-type p53. p53_T253I is a thermodynamically stabilized construct with unknown free 
energy change, A G D - N H 2 0 [35]. Furthermore, the second p53 paralog, p53_Y236F has also 
shown a higher transcriptional activity than wild type p53 , suggestion that perhaps p53 
paralogs are not only thermodynamically stable but may also contribute superior 
interactions with the p53 promoter than the wild-type. 










^ 4/ j r <y <f 4? < r jf 
Luciferase Assay 
F igure 7: T r a n s c r i p t i o n a l Activity of the p 5 3 - r e p o r t e r Gene . The fire-fly 
reporter vector containing the p53 promoter sequence was cotransfected with mock 
and p53 (wild-type) in MCF-7 cells. The bars indicate relative activity and error 
bars are the standard deviation. 
Conversely, the five other p53 constructs yielded surprising results. 
p53_S46F_S121F, the construct with two known mutants that enhanced transcriptional 
activity showed almost a 3-fold lower relative activity in comparison to the wild-type. 
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p53_S121F showed equal activity as the wild-type p53 , however, the introduction of the 
second mutations, p53_S46F, lowered the transcriptional activity. Although the D B D 
region is where D N A is attached, lowered transcriptional activity in this double mutant is 
mostly attributed to p53_S46F. Suggestion have been made by other investigators that 
perhaps the substitution of S—»F in p53_S46F causes favorable structural changes in the 
p53 protein [39]. However, perhaps the replacement of the two polar proteins in 
p53_S46F_S121F to bulky aromatic ones (S—>F) induce conformational changes to a 
greater degree and in an unfavorable manner [39]. 
Poorer is yet the p53_N239Y_S46F, which showed no activity. Although there 
is some activity in p53_S46F, it appears as if p53_N239Y inhibits the transcriptional 
activity of p53_S46F. p53_N239Y acts as a second-site suppressors for the cancer hot 
spot G245S and is transcriptionally active for the gadd45 D N A region [12, 33] . However, 
our data shows that this mutant is transcriptionally deficient for the p53 promoter 
sequence. Further studies verifying transcriptional studies are required noting our 




Identifying Super p53s 
Initial studies of our p53 mutants have identified two possible p53 mutants with 
enhanced activity. These two mutants (Y236F and T253I) have been shown by others to 
be thermodynamically stable, and show improved reporter gene activity in these 
preliminary studies. Our ultimate goal is to enhance apoptosis. We are currently in the 
process of analyzing these constructs for apoptotic abilities in caspase 3 and 9 assays in 
T47D and MCF-7 cell lines, respectively. 
Apoptosis 
Although determination of the most optimal p53 tumor suppressor protein in 
regards to the transcriptional activity and thermodynamic stability require further 
research, Y236F and T253I apoptotic analysis may reveal the potency of our combination 
of mutations against cancer. Several investigators have argued that there are no 
significant correlations between enhanced transcriptional activity and apoptosis, and that 
transactivation independent mechanism may be equally important [40]. Therefore, to 
determine apoptotic activity, we will consider caspase assays, DNA segmentation cell 
analysis, morphology, and cytochrome c release in breast cancer cells. Furthermore, we 
aim to validate the combination effect in tumors via adenovirus vector delivery in a 
human xenograft solid tumor murine model in vivo. As our current aim, the therapeutic 
effect of super p53 delivery will be tested in athymic nude mice subjected to right dorsa 
subcutaneous injection of either T47D or MCF-7 cells. 
Finally, utilizing the restoration and reactivation approaches of cellular 
mechanisms described here is more advantageous than strategies involving 
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chemotherapy, small molecule inhibitors, surgery, and hormonal therapy because 
correcting p53 associated tumorigenesis will allow the restoration and reactivation of the 
tumor suppressor activity of p53 in the cells and will also trigger apoptosis. Stabilizing 
and reactivating the tumor suppressor protein p53 provides a more effective strategy 
against aggressive cancers that presently have no effective therapies. 
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